Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Progressive Supranuclear Palsy

Neurological & Neuromuscular

Progressive Supranuclear Palsy (PSP) Clinical Trials

Also called PSP, Steele-Richardson-Olszewski syndrome, supranuclear palsy

Progressive supranuclear palsy (PSP) is a rare atypical parkinsonian disorder characterized by progressive vertical supranuclear gaze palsy (particularly impaired downward gaze), postural instability with characteristic early falls, and progressive cognitive and behavioral decline. The disease pathologically results from abnormal accumulation of hyperphosphorylated tau protein in specific brain regions including the basal ganglia, brainstem (particularly midbrain), and frontal cortex.

In plain words, progressive supranuclear palsy is a brain disease where a protein called tau builds up in areas that control movement and thinking. Over months and years, it causes trouble with balance and falls, difficulty looking down and changes in thinking.

Get an email when new Progressive Supranuclear Palsy trials open or the FDA decides. Get alerts

Progressive Supranuclear Palsy

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Progressive Supranuclear Palsy yet.

Progressive Supranuclear Palsy has no FDA-approved medicines, 41 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Progressive Supranuclear Palsy

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Progressive Supranuclear Palsy

The characteristic Richardson syndrome includes vertical gaze palsy, dystonic features affecting the neck and trunk, and progressive dementia. Additional clinical variants exist including PSP-parkinsonism with prominent parkinsonian features and PSP-cerebellar forms with predominant ataxia.

Keep reading about Progressive Supranuclear Palsy

Progressive deterioration leads to severe disability, and most people live 5 to 9 years after symptoms begin (MedlinePlus Genetics), considerably shorter than typical Parkinson disease. Unlike Parkinson disease, patients characteristically show poor or absent response to dopaminergic therapy (levodopa), which is a key diagnostic clue. MRI may show characteristic midbrain atrophy on sagittal views and hummingbird sign (rostral midbrain atrophy). Most cases occur sporadically, though rare familial forms exist.

What are the symptoms of Progressive Supranuclear Palsy?

These are common symptoms of Progressive Supranuclear Palsy, and how strong they are varies from person to person.

  • Downward gaze palsy (difficulty looking down)
  • Postural instability and frequent falls
  • Bradykinesia and rigidity
  • Cognitive decline and apathy
  • Pseudobulbar palsy with dysarthria
  • Trouble swallowing (dysphagia)

Who gets Progressive Supranuclear Palsy?

Progressive supranuclear palsy usually begins in mid to late adulthood, most often in a person's 60s, with insidious onset and gradual progression (MedlinePlus Genetics).

The condition is slightly more common in males than females. Most cases are sporadic, meaning there is no family history, and rare familial cases caused by MAPT gene variants follow an autosomal dominant pattern. PSP shows no ethnic predilection and occurs worldwide.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new Progressive Supranuclear Palsy medicines are in trials?

Investigational medicines Trial Friend tracks for Progressive Supranuclear Palsy, with trial results, safety findings and where each one stands.

How to get help paying for Progressive Supranuclear Palsy treatment

Charity funds and drugmaker programs for Progressive Supranuclear Palsy, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · CurePSP
    Quality of Life Respite Program fund
    Open

    Pays for: In-home respite care hours for caregivers.

    The foundation says: “The Quality of Life Respite Program is now accepting applications on a rolling basis as of August 2025.”
Status as each foundation showed it on November 16, 2026.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Progressive Supranuclear Palsy

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Progressive Supranuclear Palsy resources

Reputable organizations and medical references for learning more about Progressive Supranuclear Palsy, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Progressive Supranuclear Palsy

Use this Progressive Supranuclear Palsy clinical trial finder to see the 24 studies recruiting patients and 6 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 13 test a treatment and 17 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

41 active trials worldwide
Filter:
Sort:
Not yet recruitingObservational study, no treatment givenRecently updatedNCT07389018

Study to Evaluate the Feasibility of Syde® Digital Endpoints for Monitoring Patients With Progressive Supranuclear Palsy - Richardson Syndrome (PSP-R)

Sponsor: SYSNAV

The study aims to assess the feasibility/acceptability of real-world activity monitoring by the Syde® wearable device in PSP-R. The Syde® collected data will be compared to on-site conventional clinical endpoints, including functional capacity and cognitive assessments, as well as core scales assessments.

Ages 18 Years+1 location
Expected to start Jan 2027Updated yesterdayEst. Nov 2028 (~2 years)
RecruitingObservational study, no treatment givenRecently updatedNCT03225144

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Background:

Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors.

Objective:

Ages 18 Years to 110 Years1 location
Started Oct 2017Updated 6 days agoEst. Oct 2027 (~11 months)
RecruitingTreatment trialPhase 2Recently updatedNCT07173803

The Progressive Supranuclear Palsy Clinical Trial Platform

Intervention: AADvac1, LM11A-31

Sponsor: Adam Boxer

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.

Ages 41 Years to 86 Years
Started Jul 2026Updated 1 week agoEst. Sep 2030 (~3y 10m)
RecruitingTreatment trialPhase 1/2Recently updatedNCT07221344

Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies

Intervention: ARO-MAPT-SC, Placebo

Sponsor: Arrowhead Pharmaceuticals

Trial to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia...

Ages 18 Years+4 locations
Started Nov 2025Updated 1 week agoEst. Jun 2027 (~7 months)
RecruitingTreatment trialPhase 1/2Recently updatedNCT07863180

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

Intervention: Tributyrin, Placebo

Sponsor: Prabesh Kanel

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Ages 45 Years+1 location
Started Oct 2026Updated 1 week agoEst. May 2027 (~6 months)
Find Progressive Supranuclear Palsy trials near you, ranked by distance →
Active trial locations44 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+36 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Progressive Supranuclear Palsy trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Progressive Supranuclear Palsy foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Progressive Supranuclear Palsy patient communities

Facebook groups, Reddit communities and YouTube channels where Progressive Supranuclear Palsy patients, caregivers and advocacy groups talk.

Companies developing Progressive Supranuclear Palsy treatments

Drugmakers that list Progressive Supranuclear Palsy in their rare disease portfolio, 5 in all.

Questions people ask about Progressive Supranuclear Palsy